-
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
The adverse publicity following publications from the Women's Health Initiative was a multibillion dollar bonanza for compounding pharmacies providing postmenopausal hormones.
-
The authors present a series of gynecological conditions that are effectively diagnosed by hysteroscopy, including adenomyosis, chronic endometritis, Mullerian anomalies, retained fetal bones, endocervical ossification, and intrauterine abnormalities. In addition, they note that hysteroscopy can be a major part of the treatment for these conditions.
-
Davis and colleagues report the results of a one-year, randomized, controlled clinical trial of 814 women not on estrogen therapy from 65 centers in the United States, Canada, Australia, the United Kingdom, and Sweden with hypoactive sexual desire disorder treated with transdermal testosterone, 150 or 300 µg per day, or placebo.
-
Hereditary ovarian cancer syndromes are uncommon, but are most often represented by mutation in BRCA1/2.
-
-
When hospitals rely on a patient's family members to interpret medical news, they might be placing the patient at risk, an expert says.
-
Sometimes the best response to regulatory and payer changes in health care is to improve the discharge planning process.